ruboxistaurin has been researched along with Blood Pressure, High in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bean, JS; Kassab, GS; Lu, X; Rekhter, MD | 1 |
| Gilbert, RE; Gow, RM; Hepper, C; Jaworski, K; Kelly, DJ; Kemp, BE; Wilkinson-Berka, JL; Zhang, Y | 1 |
2 other study(ies) available for ruboxistaurin and Blood Pressure, High
| Article | Year |
|---|---|
Protein kinase C inhibition ameliorates functional endothelial insulin resistance and vascular smooth muscle cell hypersensitivity to insulin in diabetic hypertensive rats.
Topics: Analysis of Variance; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Glucose; Blood Pressure; Captopril; Diabetes Mellitus, Type 2; Disease Models, Animal; Dose-Response Relationship, Drug; Endothelial Cells; Femoral Artery; Hypertension; Indoles; Insulin; Insulin Resistance; Male; Maleimides; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Myography; Protein Deficiency; Protein Kinase C; Protein Kinase Inhibitors; Rats; Rats, Sprague-Dawley; Sodium Chloride, Dietary; Telemetry; Time Factors; Vasoconstriction; Vasoconstrictor Agents; Vasodilation; Vasodilator Agents | 2011 |
Protein kinase C beta inhibition attenuates the progression of experimental diabetic nephropathy in the presence of continued hypertension.
Topics: Albuminuria; Animals; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Experimental; Diabetic Angiopathies; Diabetic Nephropathies; Disease Progression; Enzyme Inhibitors; Female; Hypertension; Immunohistochemistry; Indoles; Kidney; Kidney Glomerulus; Maleimides; Organ Size; Protein Kinase C; Protein Kinase C beta; Rats; Rats, Mutant Strains; Reference Values | 2003 |